Vaxcyte, Inc. $PCVX Shares Sold by Aquatic Capital Management LLC

Aquatic Capital Management LLC lowered its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 39.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 125,785 shares of the company’s stock after selling 80,386 shares during the quarter. Aquatic Capital Management LLC owned approximately 0.10% of Vaxcyte worth $4,531,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. HighVista Strategies LLC grew its stake in Vaxcyte by 1.1% in the 2nd quarter. HighVista Strategies LLC now owns 33,457 shares of the company’s stock valued at $1,088,000 after acquiring an additional 355 shares during the period. Arizona State Retirement System increased its holdings in Vaxcyte by 1.6% in the 3rd quarter. Arizona State Retirement System now owns 34,333 shares of the company’s stock worth $1,237,000 after acquiring an additional 543 shares in the last quarter. Hsbc Holdings PLC raised its position in Vaxcyte by 4.1% during the second quarter. Hsbc Holdings PLC now owns 19,216 shares of the company’s stock worth $628,000 after acquiring an additional 755 shares during the period. Virtus Investment Advisers LLC lifted its holdings in Vaxcyte by 45.8% during the second quarter. Virtus Investment Advisers LLC now owns 2,729 shares of the company’s stock valued at $89,000 after purchasing an additional 857 shares in the last quarter. Finally, CWM LLC lifted its holdings in Vaxcyte by 55.1% during the third quarter. CWM LLC now owns 2,606 shares of the company’s stock valued at $94,000 after purchasing an additional 926 shares in the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Vaxcyte

In other news, COO Jim Wassil sold 7,395 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $58.88, for a total value of $435,417.60. Following the completion of the sale, the chief operating officer directly owned 166,818 shares in the company, valued at $9,822,243.84. This represents a 4.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Elvia Cowan sold 11,623 shares of the stock in a transaction that occurred on Tuesday, December 23rd. The shares were sold at an average price of $47.92, for a total value of $556,974.16. Following the completion of the sale, the senior vice president directly owned 14,534 shares of the company’s stock, valued at approximately $696,469.28. This represents a 44.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 31,261 shares of company stock worth $1,593,767 in the last ninety days. Insiders own 3.10% of the company’s stock.

Vaxcyte Trading Up 1.9%

NASDAQ:PCVX opened at $55.62 on Tuesday. The company has a market cap of $8.00 billion, a P/E ratio of -9.90 and a beta of 1.31. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $76.61. The company’s 50-day moving average price is $54.28 and its 200-day moving average price is $46.19.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($1.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.46) by ($0.34). During the same quarter in the prior year, the firm earned ($1.12) EPS. On average, analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

PCVX has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, January 9th. BTIG Research raised their price target on shares of Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Leerink Partners set a $77.00 price objective on Vaxcyte and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Guggenheim reiterated a “buy” rating and set a $116.00 price objective on shares of Vaxcyte in a research note on Monday, February 2nd. Finally, Needham & Company LLC raised their target price on Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $94.50.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.